NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Polyrizon Ltd. (PLRZ) Stock Analysis

Polyrizon Ltd. (PLRZ) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PLRZ

$9.20

+$0.05 (+0.55%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PLRZ with… →

PLRZ Key Statistics

As of Oct 21, 2026
Trading
Open
$9.24
Previous Close
$9.15
Day's Range
9.20–9.24
52-Week Range
2.88–18.20
Volume
6.93K
Valuation
Market Cap
$22.34M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.97
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$3.34M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.43M
1-Year Return
+34.50%
Dividend and dates
Avg Volume
61.77K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PLRZ closed at $9.20, +34.50% over 1 year.

Polyrizon Ltd. (PLRZ) has a market capitalization of $22.34M.

In fiscal 2025, PLRZ reported revenue of $0.00.

PLRZ Stock Return by Calendar Year

Polyrizon Ltd. (PLRZ) return since Oct 2024: what $10,000 became

1 year
$10,000 $13,450
+34.50%
Since Oct 2024
$10,000 $40
−99.60%

If you had invested $10,000 in Polyrizon Ltd. (PLRZ) at the close on October 29, 2024, the earliest close on record here, it would have been worth $40 at the close on October 21, 2026: −99.60% in total, −93.91% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+8.36%
2025−99.74%
2024 (partial year)+40.00%

As of October 21, 2026.

PLRZ Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$3.34M—
2024$0.00−$1.55M—
2023$0.00−$600.00K—
2022$0.00−$779.00K—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$5.79M−$3.34M—
2024$0.00—−$1.30M−$1.55M—
2023$0.00—−$635.00K−$600.00K—
2022$0.00—−$895.00K−$779.00K—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Polyrizon Ltd. (PLRZ) at $22.34M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 2 employees.

PLRZ last closed at $9.20 on October 21, 2026. That is +$0.05 (+0.55%) against the previous close. Over the past 52 weeks the price has ranged from $2.88 to $18.20. The latest close sits 219.44% above that 52-week low.

Financial Health

In fiscal 2025, Polyrizon Ltd. reported revenue of $0.00. The same year closed with a net loss of $3.34M. Trailing earnings per share are −4.97.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Daily returns over the trailing 2 years annualize to a volatility of 338.9%. Over the trailing twelve months the total return is +34.50%. The stored price history starts on October 29, 2024, and the total return since then is −99.60%.

Growth & Income

No dividend is on file for PLRZ.

The record holds one complete calendar year, 2025, which returned −99.74%. So far in 2026 the total return is +8.36%.

Peer Comparison

Polyrizon Ltd. (PLRZ) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Polyrizon Ltd. PLRZ $22.34M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Polyrizon Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Polyrizon Ltd.

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.

Visit website →